In order to further strengthen the exchanges and cooperation between China and the United States in the field of drug standards and improve the quality control of pharmaceuticals, the National Pharmacopoeia Commission of China and the US Pharmacopoeia Commission jointly organized the Third China-US Pharmacopoeia High-level Forum in Tianjin on November 5-7. The theme is "Drug Quality Control and Standards." Nguyen Wu, Deputy Secretary of the State Food and Drug Administration and Secretary General of the National Pharmacopoeia Commission, and Roger L. Williams, Executive Vice President and Chief Executive Officer of the US Pharmacopoeia Commission attended the meeting and delivered keynote speeches.
The reporter was informed at the meeting that both China and the United States will further strengthen cooperation in drug standards and quality control. At present, the work involved in the “Memorandum of Understanding on the Cooperation between the China National Pharmacopoeia Committee and the US Pharmacopoeia Commission†(2008-2010) has been fully launched. The working groups are actively organizing work in accordance with work plans jointly determined by both parties. Some of the cooperation projects have entered Specific implementation stage.
Chaoyang industry cooperation has broad prospects
In order to further consolidate and develop the results of exchanges and cooperation between China and the United States in the field of drug standards, and further broaden the areas for exchanges and cooperation, and comprehensively establish a mechanism for long-term exchanges and cooperation between the two sides, China and the United States have adopted the principle of equality, mutual trust, mutual benefit, and win-win. The round of consultations formally signed the Memorandum of Understanding on Sino-U.S. Cooperation this year.
The Sino-U.S. Cooperation Memorandum of Understanding has laid a solid foundation for both parties to conduct all-round exchanges and cooperation in the field of drug standards. Over the past six months, after several rounds of active consultations, we have initially proposed specific cooperation in high-level exchanges, academic exchanges, personnel exchanges and training, standards and safety information exchange, promotion of the two pharmacopoeias, joint formulation of drug standards, and export drug certification. The plan has opened up a good start for exchanges and cooperation in the next three years. In the next stage, we must further implement the various contents of the Sino-U.S. Cooperation Memorandum of Understanding, refine and implement the specific details of the cooperation between the parties in all aspects, and work together to continuously improve the quality of medicines.
With the rapid development of the pharmaceutical industry, the quality and safety of medicines have attracted unprecedented attention from countries, and the role of drug standards in international trade has become increasingly prominent. China is the largest developing country in the world. The pharmaceutical industry is a sunrise industry with great potential for development in China. The United States has the most advanced modern pharmaceutical industry in the world, and in the international context of global economic globalization and the accelerating process of integration, China The United States and the United States have broad prospects for exchanges and cooperation in the field of drug standards.
Further promote the internationalization of Chinese medicine standards
Wu Hao expressed at the forum that it is necessary to consolidate the achievements of development and continue to broaden the field of exchanges and cooperation, and push forward the cooperation and exchange of pharmaceutical standards between China and the United States. He pointed out that China and the United States should further strengthen cooperation and coordination in the fields of traditional medicine and botanicals. China has thousands of years of practice in the application of traditional medicine. China has done a lot of work in the quality control of traditional medicines, and the quality control of traditional Chinese medicine ranks among the top in the world. At present, China has established a relatively complete Chinese medicine standard system based on the "Chinese Pharmacopoeia", and has accumulated rich management and technical experience in the work of traditional Chinese medicine standards. In addition, with the rapid development of trade in pharmaceutical products between China and the United States, the importance of drug standard substances in pharmaceutical supervision has become increasingly prominent, and the exchange and cooperation between the two parties in drug standards should be further strengthened.
Roger L. Williams, executive vice president and chief executive officer of the US Pharmacopoeia Commission, stated that the US Pharmacopoeia Commission is implementing an internationalization strategy based on maintaining relevance and importance in the U.S. market, establishing partnerships with stakeholders, and The projects and strategies of developing countries and the establishment of branches in appropriate places outside the United States seek to develop into an international organization. One of the important areas for the development of the United States Pharmacopoeia is Southeast Asia. China is a very important partner. The US Pharmacopoeia Commission has established branches in Shanghai. Roger L.Williams hopes to get more support from the Chinese side in formulating Chinese medicine standards.
According to the Memorandum of Understanding on Sino-U.S. Cooperation, at present, the two parties have reached a consensus on the working procedures for jointly formulating Chinese medicine standards. In the next stage, it is necessary to continue to elaborate on specific details such as collection methods, standard formats, and types of cooperation in advance. And implement it. Wu Hao pointed out that the most critical issue is the standard issue of Chinese medicine to achieve internationalization and make greater contributions to the health care of the people of the world. We must make full use of the coordination results to promote the internationalization of Chinese medicine standards.
The reporter was informed at the meeting that both China and the United States will further strengthen cooperation in drug standards and quality control. At present, the work involved in the “Memorandum of Understanding on the Cooperation between the China National Pharmacopoeia Committee and the US Pharmacopoeia Commission†(2008-2010) has been fully launched. The working groups are actively organizing work in accordance with work plans jointly determined by both parties. Some of the cooperation projects have entered Specific implementation stage.
Chaoyang industry cooperation has broad prospects
In order to further consolidate and develop the results of exchanges and cooperation between China and the United States in the field of drug standards, and further broaden the areas for exchanges and cooperation, and comprehensively establish a mechanism for long-term exchanges and cooperation between the two sides, China and the United States have adopted the principle of equality, mutual trust, mutual benefit, and win-win. The round of consultations formally signed the Memorandum of Understanding on Sino-U.S. Cooperation this year.
The Sino-U.S. Cooperation Memorandum of Understanding has laid a solid foundation for both parties to conduct all-round exchanges and cooperation in the field of drug standards. Over the past six months, after several rounds of active consultations, we have initially proposed specific cooperation in high-level exchanges, academic exchanges, personnel exchanges and training, standards and safety information exchange, promotion of the two pharmacopoeias, joint formulation of drug standards, and export drug certification. The plan has opened up a good start for exchanges and cooperation in the next three years. In the next stage, we must further implement the various contents of the Sino-U.S. Cooperation Memorandum of Understanding, refine and implement the specific details of the cooperation between the parties in all aspects, and work together to continuously improve the quality of medicines.
With the rapid development of the pharmaceutical industry, the quality and safety of medicines have attracted unprecedented attention from countries, and the role of drug standards in international trade has become increasingly prominent. China is the largest developing country in the world. The pharmaceutical industry is a sunrise industry with great potential for development in China. The United States has the most advanced modern pharmaceutical industry in the world, and in the international context of global economic globalization and the accelerating process of integration, China The United States and the United States have broad prospects for exchanges and cooperation in the field of drug standards.
Further promote the internationalization of Chinese medicine standards
Wu Hao expressed at the forum that it is necessary to consolidate the achievements of development and continue to broaden the field of exchanges and cooperation, and push forward the cooperation and exchange of pharmaceutical standards between China and the United States. He pointed out that China and the United States should further strengthen cooperation and coordination in the fields of traditional medicine and botanicals. China has thousands of years of practice in the application of traditional medicine. China has done a lot of work in the quality control of traditional medicines, and the quality control of traditional Chinese medicine ranks among the top in the world. At present, China has established a relatively complete Chinese medicine standard system based on the "Chinese Pharmacopoeia", and has accumulated rich management and technical experience in the work of traditional Chinese medicine standards. In addition, with the rapid development of trade in pharmaceutical products between China and the United States, the importance of drug standard substances in pharmaceutical supervision has become increasingly prominent, and the exchange and cooperation between the two parties in drug standards should be further strengthened.
Roger L. Williams, executive vice president and chief executive officer of the US Pharmacopoeia Commission, stated that the US Pharmacopoeia Commission is implementing an internationalization strategy based on maintaining relevance and importance in the U.S. market, establishing partnerships with stakeholders, and The projects and strategies of developing countries and the establishment of branches in appropriate places outside the United States seek to develop into an international organization. One of the important areas for the development of the United States Pharmacopoeia is Southeast Asia. China is a very important partner. The US Pharmacopoeia Commission has established branches in Shanghai. Roger L.Williams hopes to get more support from the Chinese side in formulating Chinese medicine standards.
According to the Memorandum of Understanding on Sino-U.S. Cooperation, at present, the two parties have reached a consensus on the working procedures for jointly formulating Chinese medicine standards. In the next stage, it is necessary to continue to elaborate on specific details such as collection methods, standard formats, and types of cooperation in advance. And implement it. Wu Hao pointed out that the most critical issue is the standard issue of Chinese medicine to achieve internationalization and make greater contributions to the health care of the people of the world. We must make full use of the coordination results to promote the internationalization of Chinese medicine standards.
Leisuwash specializing in manufacture Automatic Car Wash Machine, Touchless Car Wash , Automatic Touchless Car Wash, touchless car wash equipment, robot car wash, smart car wash system, leisuwash 360, leisuwash leibao 360, laserwash 360, leisuwash touchless car wash machine, leisu wash touchless car wash automatic, leisu wash 360 high pressure touchless car wash equipment, robo car wash, touch free car wash, leisuwash 360 touch free car wash, leisuwash 360 price, automatic car wash price, leisuwash in malaysia, no touch automatic car wash machine.
Leisuwash 360 touchless car wash machine high intelligent high quality, with car wash + car care + drying process totally, each car wash takes time 1 minute to 5 minutes which depends on the car wash mode.
Automatic touch free car wash equipment more and more popular in car wash business market, as can save employee fees and wash time mostly, bring investor much more benefit profit return. That's why choose the automatic car washing system.
Touch Free Car Wash Equipment,Automatic Car Wash,Leisuwash Touchless Car Wash,Automatic Car Wash Machine
Hangzhou Leisu Cleaning Equipment Co.,Ltd , https://www.sdleisuwashtouchless.com